Press Releases

ASRS Top 10 awarded to Palatin’s pre-clinical diabetic retinopathy poster demonstrating positive effects of melanocortin agonists for retinal inflammation Oct 22, 2021, 07:30 ET CRANBURY, N.J., Oct. 22, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide […]

– Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Currently Expected to Start Next Quarter with Top-Line Results Expected in the Second Half Calendar 2022 – Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis Currently Expected to Start Next Quarter with Top-Line Results Expected in the Second Half

Sep 27, 2021, 07:30 ET CRANBURY, N.J., Sept. 27, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced the presentation of the protective effects of melanocortin 1 receptor agonists PL8331 and PL9654 in mouse models

Sep 24, 2021, 07:30 ET CRANBURY, N.J., Sept. 24, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2021 operating results on Wednesday, September 29, 2021, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted

– CEO to present Palatin’s world-class expertise in melanocortins and discuss its agonist programs to treat inflammation – Head of Preclinical Research to present posters on the utility of melanocortins to treat inflammation and specific data in an inflammatory disease model Sep 15, 2021, 07:30 ET CRANBURY, N.J., Sept. 15, 2021 /PRNewswire/ — Palatin Technologies, Inc.

Sep 13, 2021, 07:00 ET CRANBURY, N.J., Sept. 13, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced that Carl Spana, Ph.D., President and Chief Executive Officer, will participate in the H.C. Wainwright 23rd

Dry Eye and the Need for Innovation Topics: Melanocortins’ role in resolving inflammation and Phase 2 study results with Palatin’s compound PL9643 for dry eye disease On Track to initiate Phase 3 study calendar Q4 2021 with data expected calendar 2H 2022 Jul 22, 2021, 17:28 ET CRANBURY, N.J., July 22, 2021 /PRNewswire/ — Palatin

– Limited to Proposal 3, Amendment to Certificate of Incorporation to Increase Authorized Common Stock – Scheduled to Reconvene August 6, 2021, 9:00 am Eastern Daylight Time Jul 08, 2021, 16:15 ET CRANBURY, N.J., July 8, 2021 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) (NYSE American: PTN) announced that its 2021 Annual Meeting of Stockholders that convened

Palatin and FDA Reach Agreement on Path to NDA Submission, including Trial Design, Endpoints, Interim Assessment, and Patient Population On Track to Initiate Phase 3 Study Calendar Q4 2021 with Data Expected Calendar 2H 2022 Jun 29, 2021, 07:30 ET CRANBURY, N.J., June 29, 2021 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) (NYSE American: PTN) a

Michael B. Raizman, M.D. – Chief Medical Officer James E. Hattersley – Senior Vice President, Business Development J. Don Wang, Ph.D. – Vice President, Product Development Jun 28, 2021, 07:30 ET CRANBURY, N.J., June 28, 2021 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) (NYSE American: PTN) a biopharmaceutical company developing first-in-class medicines based on molecules that